These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 22172033)
1. Epigenetic regulation of osteoclast differentiation. Yasui T; Hirose J; Aburatani H; Tanaka S Ann N Y Acad Sci; 2011 Dec; 1240():7-13. PubMed ID: 22172033 [TBL] [Abstract][Full Text] [Related]
2. Epigenetic regulation of osteoclast differentiation: possible involvement of Jmjd3 in the histone demethylation of Nfatc1. Yasui T; Hirose J; Tsutsumi S; Nakamura K; Aburatani H; Tanaka S J Bone Miner Res; 2011 Nov; 26(11):2665-71. PubMed ID: 21735477 [TBL] [Abstract][Full Text] [Related]
3. RANKL induces NFATc1 acetylation and stability via histone acetyltransferases during osteoclast differentiation. Kim JH; Kim K; Youn BU; Jin HM; Kim JY; Moon JB; Ko A; Seo SB; Lee KY; Kim N Biochem J; 2011 Jun; 436(2):253-62. PubMed ID: 21413932 [TBL] [Abstract][Full Text] [Related]
4. The molecular understanding of osteoclast differentiation. Asagiri M; Takayanagi H Bone; 2007 Feb; 40(2):251-64. PubMed ID: 17098490 [TBL] [Abstract][Full Text] [Related]
5. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL. Kim HN; Ha H; Lee JH; Jung K; Yang D; Woo KM; Lee ZH Eur J Pharmacol; 2009 Nov; 623(1-3):22-9. PubMed ID: 19766111 [TBL] [Abstract][Full Text] [Related]
6. MHC class II transactivator negatively regulates RANKL-mediated osteoclast differentiation by downregulating NFATc1 and OSCAR. Kim JH; Kim K; Youn BU; Jin HM; Kim N Cell Signal; 2010 Sep; 22(9):1341-9. PubMed ID: 20466061 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1. Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185 [TBL] [Abstract][Full Text] [Related]
8. [Epigenetic regulation of osteoclastogenesis by histone modification]. Omata Y; Tanaka S Clin Calcium; 2012 May; 22(5):619-28. PubMed ID: 22549185 [TBL] [Abstract][Full Text] [Related]
9. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically. Valverde P; Tu Q; Chen J J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638 [TBL] [Abstract][Full Text] [Related]
10. Negative feedback loop of bone resorption by NFATc1-dependent induction of Cadm1. Nakamura S; Koyama T; Izawa N; Nomura S; Fujita T; Omata Y; Minami T; Matsumoto M; Nakamura M; Fujita-Jimbo E; Momoi T; Miyamoto T; Aburatani H; Tanaka S PLoS One; 2017; 12(4):e0175632. PubMed ID: 28414795 [TBL] [Abstract][Full Text] [Related]
11. Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells. Mohamed SG; Sugiyama E; Shinoda K; Taki H; Hounoki H; Abdel-Aziz HO; Maruyama M; Kobayashi M; Ogawa H; Miyahara T Bone; 2007 Oct; 41(4):592-602. PubMed ID: 17627913 [TBL] [Abstract][Full Text] [Related]
12. Harmine, a β-carboline alkaloid, inhibits osteoclast differentiation and bone resorption in vitro and in vivo. Yonezawa T; Hasegawa S; Asai M; Ninomiya T; Sasaki T; Cha BY; Teruya T; Ozawa H; Yagasaki K; Nagai K; Woo JT Eur J Pharmacol; 2011 Jan; 650(2-3):511-8. PubMed ID: 21047508 [TBL] [Abstract][Full Text] [Related]
13. Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2. Nishida S; Tsubaki M; Hoshino M; Namimatsu A; Uji H; Yoshioka S; Tanimori Y; Yanae M; Iwaki M; Irimajiri K Biochem Biophys Res Commun; 2005 Mar; 328(1):91-7. PubMed ID: 15670755 [TBL] [Abstract][Full Text] [Related]
14. The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling. Yang J; Park OJ; Lee YJ; Jung HM; Woo KM; Choi Y Eur J Immunol; 2008 Jun; 38(6):1598-609. PubMed ID: 18421790 [TBL] [Abstract][Full Text] [Related]
15. Regulatory mechanism of NFATc1 in RANKL-induced osteoclast activation. Song I; Kim JH; Kim K; Jin HM; Youn BU; Kim N FEBS Lett; 2009 Jul; 583(14):2435-40. PubMed ID: 19576893 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of osteoclast differentiation and bone resorption by rotenone, through down-regulation of RANKL-induced c-Fos and NFATc1 expression. Kwak HB; Lee BK; Oh J; Yeon JT; Choi SW; Cho HJ; Lee MS; Kim JJ; Bae JM; Kim SH; Kim HS Bone; 2010 Mar; 46(3):724-31. PubMed ID: 19900598 [TBL] [Abstract][Full Text] [Related]
17. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis. Kanazawa K; Kudo A J Bone Miner Res; 2005 May; 20(5):840-7. PubMed ID: 15824857 [TBL] [Abstract][Full Text] [Related]
18. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal. Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of osteoclastogenic differentiation by Ikarisoside A in RAW 264.7 cells via JNK and NF-kappaB signaling pathways. Choi HJ; Park YR; Nepal M; Choi BY; Cho NP; Choi SH; Heo SR; Kim HS; Yang MS; Soh Y Eur J Pharmacol; 2010 Jun; 636(1-3):28-35. PubMed ID: 20353769 [TBL] [Abstract][Full Text] [Related]
20. Identification of NFAT binding sites that mediate stimulation of cathepsin K promoter activity by RANK ligand. Balkan W; Martinez AF; Fernandez I; Rodriguez MA; Pang M; Troen BR Gene; 2009 Oct; 446(2):90-8. PubMed ID: 19563866 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]